but1 Antibody

Shipped with Ice Packs
In Stock

Description

Structure and Mechanism of Action

The Butyrophilin 1A1 antibody targets the BTN1A1 protein, a member of the butyrophilin family. Structurally, the antibody is designed as a full-length IgG1 molecule with high specificity for the extracellular domain of BTN1A1. Its mechanism involves blocking the protein's ability to suppress T-cell activation, thereby enhancing anti-tumor immune responses.

CharacteristicDetail
TargetButyrophilin 1A1 (BTN1A1)
Antibody TypeMonoclonal IgG1
Binding SiteExtracellular domain of BTN1A1 (Ala27-Arg242)
Species OriginHumanized or chimeric (under development)

Research Findings

Recent studies highlight the antibody's therapeutic potential:

Key Study Results

A preclinical study in tumor-bearing mice demonstrated:

  • Tumor Growth Suppression: Antibody-mediated blockade of BTN1A1 inhibited tumor growth by 60% compared to controls .

  • T-Cell Activation: BTN1A1 suppression restored CD4+ and CD8+ T-cell infiltration into the tumor microenvironment .

  • Mutual Exclusivity with PD-L1: BTN1A1 expression inversely correlated with PD-L1 levels, suggesting it as a complementary target for PD-1/PD-L1-refractory cancers .

OutcomeMeasurementResult
Tumor Volume ReductionTumor weight (mg)40% reduction
T-Cell InfiltrationCD8+ T-cell density3.2-fold increase
PD-L1 ExpressionRT-qPCR analysisNegative correlation (r = -0.8)

Therapeutic Applications

The Butyrophilin 1A1 antibody is currently in early-stage development for:

  • Solid Tumors: Studies focus on cancers with low PD-L1 expression, including melanoma and colorectal carcinoma .

  • Immune Evasion: Its ability to counteract T-cell suppression in PD-1/PD-L1-resistant tumors positions it as a next-generation immunotherapy .

Pipeline Progress

  • Preclinical: Completed efficacy testing in syngeneic mouse models .

  • Clinical: Phase I trials expected to commence in 2026, targeting refractory cancers .

Comparative Analysis with Existing Checkpoints

FeaturePD-1/PD-L1BTN1A1
Expression PatternVariable across tumor typesMutually exclusive with PD-L1
Tumor ResponseLimited to PD-L1+ tumorsEffective in PD-L1 negative
Resistance MechanismAdaptive upregulationIntrinsic suppression

Challenges and Future Directions

  • Antigen Heterogeneity: Variable BTN1A1 expression across tumor types necessitates biomarker-driven trials .

  • Combination Therapies: Synergy with bispecific antibodies (e.g., dual targeting of CD19 and CD3) is under exploration .

  • Toxicity Profiling: Preclinical data suggest minimal off-target effects, but human trials will validate safety .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
but1 antibody; mug107 antibody; SPAC27D7.12c antibody; Uba3-binding protein but1 antibody; Meiotically up-regulated gene 107 protein antibody
Target Names
but1
Uniprot No.

Target Background

Function
But1 Antibody functions as a negative regulator of the NEDD8 pathway. It plays a role in meiosis.
Database Links
Subcellular Location
Nucleus.

Q&A

What is BUT1 protein and what is its function in Schizosaccharomyces pombe?

BUT1 (also known as mug107 or SPAC27D7.12c) is a Uba3-binding protein involved in the neddylation pathway in fission yeast . It functions as a meiotically up-regulated gene product that appears to be regulated by the transcription factor Phx1, which contributes to long-term survival and stress tolerance . While specific molecular mechanisms remain under investigation, BUT1 likely plays a role in protein modification through the neddylation process, which is essential for various cellular functions including cell cycle progression and stress response.

The protein has been identified as part of studies investigating gene expression changes during stationary phase and stress conditions. Research indicates that BUT1/mug107 expression decreases in Δphx1 mutants, suggesting its regulation by the Phx1 transcription factor that contributes to long-term survival mechanisms .

What types of BUT1 antibodies are available for research applications?

Currently, polyclonal antibodies against BUT1 from Schizosaccharomyces pombe are commercially available for research purposes. These include:

  • Rabbit anti-Schizosaccharomyces pombe BUT1 Polyclonal Antibody (specificity for strain 972/ATCC 24843)

  • Preparations in different quantities (standard 2ml/0.1ml formats and larger 10mg quantities)

These antibodies have been validated for applications including:

  • Western blotting (WB)

  • Enzyme-linked immunosorbent assay (ELISA)

While monoclonal antibodies might provide higher specificity for certain applications, the literature search results do not indicate commercially available monoclonal BUT1 antibodies at this time.

How should I design experiments using BUT1 antibody for cell cycle studies in fission yeast?

When designing experiments to study BUT1 involvement in cell cycle regulation, consider implementing synchronized cell cultures using the temperature-sensitive cdc25-22 allele method. This approach allows collection of sufficient quantities of synchronized cells for downstream applications like ChIP .

Recommended experimental approach:

  • Cell synchronization protocol:

    • Use temperature-sensitive cdc25-22 allele to arrest cells in G2 phase

    • Monitor synchronization by determining septation index (should reach 60-80% during S phase)

    • Collect ~5 μL culture at each time point to verify synchronization

  • Sample processing for BUT1 detection:

    • Fix cells at defined time points after synchronization release

    • Process for antibody-based detection methods (immunofluorescence or Western blotting)

    • Include appropriate controls (see section 2.4)

  • Data collection parameters:

    • Monitor BUT1 localization/abundance throughout cell cycle phases

    • Correlate with cell cycle markers and cellular structures

    • Quantify changes in protein levels or localization patterns

This approach will allow you to determine if BUT1 exhibits cell cycle-dependent regulation similar to other proteins involved in critical cellular processes like chromosome segregation in fission yeast .

What is the optimal protocol for using BUT1 antibody in Western blotting?

Western blotting with BUT1 antibody requires careful optimization to ensure specificity and sensitivity. Based on general principles for fission yeast proteins and the specific characteristics of BUT1:

Recommended Western blot protocol:

  • Sample preparation:

    • Harvest ~10⁷ cells from appropriate culture conditions

    • Extract proteins using either:

      • SDS/mercaptoethanol buffer (effective for cell wall-associated proteins)

      • Standard lysis buffer with protease inhibitors

  • Gel electrophoresis parameters:

    • Use 10-12% SDS-PAGE for optimal resolution (BUT1 is approximately 55kDa)

    • Load 20-40 μg total protein per lane

    • Include positive control (recombinant BUT1 if available)

  • Transfer and antibody incubation:

    • Transfer to PVDF membrane (0.45 μm pore size)

    • Block with 5% non-fat milk in TBST for 1 hour at room temperature

    • Incubate with BUT1 antibody at 1:1000 dilution overnight at 4°C

    • Wash thoroughly with TBST (4 × 5 minutes)

    • Incubate with appropriate secondary antibody (anti-rabbit IgG-HRP) at 1:5000 dilution

  • Detection and troubleshooting:

    • Use enhanced chemiluminescence for detection

    • Expected band size: ~55 kDa (verify against protein marker)

    • If background is high, increase blocking time or adjust antibody concentration

Remember that protein extraction from fission yeast can be challenging due to the rigid cell wall. Efficient cell lysis is critical for successful protein detection.

How can I optimize BUT1 antibody for immunofluorescence microscopy in fission yeast?

Immunofluorescence with fission yeast requires special considerations for cell wall digestion and fixation. For BUT1 detection:

Optimized immunofluorescence protocol:

  • Cell preparation:

    • Grow cells to appropriate density in selective medium

    • For cell cycle studies, synchronize using cdc25-22 temperature shift

    • Fix cells with 3.7% formaldehyde for 30 minutes

  • Cell wall digestion:

    • Treat with zymolyase (1 mg/mL) in PEMS buffer for 30-60 minutes at 37°C

    • Monitor digestion microscopically

    • Permeabilize with 1% Triton X-100 for 5 minutes

  • Antibody incubation:

    • Block with 1% BSA in PBS for 1 hour at room temperature

    • Incubate with BUT1 primary antibody (1:100-1:500 dilution) overnight at 4°C

    • Wash 3× with PBS-T

    • Incubate with fluorescently-labeled secondary antibody (1:500) for 1 hour

    • Counterstain with DAPI (1 μg/mL) to visualize nuclei

  • Imaging considerations:

    • Use confocal microscopy for optimal resolution

    • Capture Z-stacks to properly assess localization patterns

    • Include appropriate controls (see section 2.4)

For accurate localization studies, consider co-staining with markers for specific cellular compartments (nucleus, centromeres, cell wall) to determine BUT1's precise subcellular distribution.

What controls are necessary when using BUT1 antibody in experimental setups?

Proper controls are essential for interpreting antibody-based experiments accurately. When working with BUT1 antibody, include the following controls:

Essential controls for BUT1 antibody experiments:

  • Specificity controls:

    • Negative control: Extract from a BUT1 knockout strain (Δbut1) if available

    • Blocking peptide control: Pre-incubate antibody with excess BUT1 peptide antigen

    • Isotype control: Use non-specific rabbit IgG at the same concentration

  • Technical controls:

    • Secondary antibody only: Omit primary antibody to detect non-specific binding

    • Loading control: Use antibody against housekeeping protein (e.g., tubulin, actin)

    • Positive control: If studying induced conditions, include samples where BUT1 is known to be expressed

  • Additional controls for immunofluorescence:

    • Autofluorescence control: Unstained cells to assess natural fluorescence

    • Single channel controls: For multicolor imaging to determine bleed-through

Control TypePurposeImplementation
Negative ControlValidate specificityUse Δbut1 strain extract
Blocking PeptideConfirm antibody specificityPre-incubate antibody with antigen
Isotype ControlDetect non-specific bindingUse matched concentration of non-specific IgG
Secondary OnlyDetect secondary antibody backgroundOmit primary antibody
Loading ControlNormalize protein amountsProbe for housekeeping protein

These controls will help distinguish genuine BUT1 signal from experimental artifacts and non-specific binding.

How can BUT1 antibody be utilized in chromatin immunoprecipitation (ChIP) experiments?

ChIP experiments using BUT1 antibody can help determine if BUT1 associates with chromatin and specific DNA regions. This is particularly relevant given the potential role of BUT1 in meiosis and stress response through transcriptional regulation pathways.

ChIP protocol for BUT1:

  • Sample preparation:

    • Grow cells to appropriate density (minimum 50 mL culture)

    • For cell cycle studies, synchronize using cdc25-22 method

    • Cross-link with 1% formaldehyde for 15 minutes at room temperature

    • Quench with 125 mM glycine for 5 minutes

  • Chromatin preparation:

    • Lyse cells with glass beads in lysis buffer containing protease inhibitors

    • Sonicate to generate DNA fragments of 200-500 bp

    • Verify fragmentation by agarose gel electrophoresis

    • Pre-clear chromatin with Protein A/G beads

  • Immunoprecipitation:

    • Incubate chromatin with BUT1 antibody (5-10 μg) overnight at 4°C

    • Add Protein A/G beads and incubate for 2-3 hours

    • Wash beads extensively with increasing salt concentrations

    • Elute protein-DNA complexes and reverse cross-links

  • Analysis methods:

    • qPCR analysis: For specific target regions

    • Dot blot hybridization: For repetitive sequences like telomeres

    • Next-generation sequencing: For genome-wide binding profile

Given the potential link between BUT1 and transcriptional regulation during stress and meiosis, focus ChIP analysis on promoter regions of genes involved in these processes to identify potential regulatory relationships.

How does BUT1 antibody perform in proximity ligation assays (PLA) to study protein interactions?

Proximity ligation assay (PLA) is an advanced technique to visualize protein-protein interactions in situ with high sensitivity. For BUT1 interaction studies:

PLA protocol optimization:

  • Cell preparation:

    • Follow standard immunofluorescence protocol for fission yeast

    • Fix and permeabilize cells as described in section 2.3

    • Block with Duolink blocking solution

  • Primary antibody incubation:

    • Incubate with BUT1 antibody (1:100-1:200)

    • Co-incubate with antibody against potential interaction partner

    • Ensure antibodies are from different host species

  • PLA-specific steps:

    • Add PLA probes against host species of both primary antibodies

    • Perform ligation and amplification according to manufacturer's protocol

    • Counterstain nuclei with DAPI

  • Analysis considerations:

    • Quantify PLA signals per cell

    • Compare signal intensity across different conditions

    • Include appropriate negative controls (single antibody, non-interacting protein)

Based on BUT1's function in the neddylation pathway, potential interaction partners to investigate include:

  • Uba3 (known binding partner)

  • Components of the neddylation machinery

  • Stress response factors regulated by Phx1

How can I use BUT1 antibody to investigate protein expression changes during stress conditions?

BUT1 may play a role in stress response pathways, as it's regulated by Phx1, a transcription factor involved in long-term survival and stress tolerance . To investigate BUT1 expression changes:

Stress response experimental design:

  • Stress induction conditions:

    • Oxidative stress: 0.5-2 mM H₂O₂ for 15-60 minutes

    • Nutrient limitation: Transfer to nitrogen-free or glucose-limited media

    • Stationary phase: Culture for 80+ hours to reach stationary phase

    • Heat shock: 39-42°C for 15-30 minutes

  • Sample collection:

    • Harvest cells at multiple time points post-stress

    • Include pre-stress baseline samples

    • Process for Western blot or immunofluorescence

  • Quantitative analysis:

    • Measure BUT1 protein levels by Western blot densitometry

    • Normalize to loading control (actin or tubulin)

    • Calculate fold change relative to unstressed condition

  • Correlation with phenotypic data:

    • Monitor cell viability under stress conditions

    • Compare wild-type and Δphx1 strains

    • Assess potential correlation between BUT1 levels and survival rates

This approach will help establish if BUT1 is part of the cellular stress response system and whether its regulation is critical for adaptation to adverse conditions.

What are common issues with BUT1 antibody specificity and how can they be addressed?

When working with BUT1 antibody, several specificity issues may arise:

Common specificity issues and solutions:

  • High background in Western blots:

    • Issue: Non-specific binding to multiple proteins

    • Solution: Increase blocking time (2-3 hours), use 5% BSA instead of milk, increase wash stringency, titrate antibody concentration

  • Multiple bands in Western blot:

    • Issue: Cross-reactivity or post-translational modifications

    • Solution: Verify with knockout control, use blocking peptide, optimize extraction conditions to prevent proteolysis

  • Weak or no signal:

    • Issue: Insufficient protein extraction or antibody concentration

    • Solution: Optimize extraction method for cell wall proteins, increase antibody concentration, extend incubation time

  • Inconsistent results between experiments:

    • Issue: Variability in experimental conditions

    • Solution: Standardize growth conditions, use fresh antibody aliquots, maintain consistent incubation parameters

When troubleshooting, always return to fundamental controls and consider testing multiple antibody lots if available. For fission yeast proteins, extraction efficiency is often a critical factor in successful detection.

How do experimental conditions affect BUT1 antibody performance in different applications?

Various experimental conditions can significantly impact BUT1 antibody performance:

Critical parameters affecting antibody performance:

ParameterWestern BlotImmunofluorescenceChIP
FixationN/ACritical (3.7% formaldehyde optimal)Critical (1% formaldehyde, 15 min)
Cell wall digestionNot applicableEssential (use zymolyase)Not required (sonication breaks cells)
Antibody dilution1:1000-1:20001:100-1:5005-10 μg per reaction
Incubation timeOvernight at 4°COvernight at 4°COvernight at 4°C
Buffer compositionTBS-T with 5% milk/BSAPBS with 1% BSAIP buffer with protease inhibitors
Detection methodHRP-conjugated secondaryFluorescent secondaryqPCR or sequencing

Optimization recommendations:

  • For Western blotting, test multiple extraction methods if signal is weak

  • For immunofluorescence, optimize cell wall digestion time carefully

  • For ChIP, test different sonication conditions to achieve optimal DNA fragmentation

Each application requires specific optimization of these parameters for successful BUT1 detection.

How can I validate new lots of BUT1 antibody for experimental consistency?

Antibody lot-to-lot variation can significantly impact experimental results. To validate new lots:

Antibody validation protocol:

  • Initial quality control:

    • Check appearance (no visible precipitates)

    • Verify concentration (Bradford assay or A280 measurement)

    • Confirm host species and clonality match specifications

  • Performance comparison:

    • Run side-by-side Western blots with old and new lots

    • Use identical samples and conditions

    • Quantify band intensity and background

    • Calculate signal-to-noise ratio for comparison

  • Titration analysis:

    • Test multiple dilutions (e.g., 1:500, 1:1000, 1:2000)

    • Determine optimal working concentration

    • Compare with previous lot's optimal concentration

  • Specificity validation:

    • Confirm absence of signal in knockout/negative control

    • Verify expected molecular weight of detected protein

    • Test blocking peptide competition if available

Document all validation results for future reference, including optimal working dilutions for each application and lot number.

How do I interpret contradictory results when using BUT1 antibody in different experimental systems?

Contradictory results with BUT1 antibody across different experimental systems require systematic troubleshooting:

Approach to resolving contradictory results:

  • Verify antibody specificity:

    • Confirm signal absence in knockout/negative controls

    • Perform blocking peptide competition

    • Test multiple antibody dilutions to optimize signal-to-noise ratio

  • Evaluate experimental differences:

    • Growth conditions: BUT1 expression may vary with growth phase and stress conditions

    • Extraction methods: Different lysis protocols may affect protein recovery

    • Detection systems: Sensitivity varies between ECL systems or microscope settings

  • Consider biological variables:

    • Cell cycle stage: BUT1 might be cell cycle-regulated (synchronize cultures for comparison)

    • Strain differences: Genetic background may affect expression or modification

    • Post-translational modifications: These may vary between conditions

  • Resolution strategies:

    • Use multiple detection methods (e.g., both Western blot and immunofluorescence)

    • Implement more controls to identify variables affecting results

    • Quantify results with appropriate statistical analysis

When contradictory results persist, consider that they may reflect genuine biological complexity rather than technical issues.

What are the implications of BUT1 localization patterns for understanding its function?

Analyzing BUT1 localization can provide valuable insights into its function:

Interpretation framework for localization data:

  • Nuclear localization:

    • May indicate involvement in transcriptional regulation

    • Could suggest role in meiotic processes (consistent with meiotic upregulation)

    • Consider co-localization with chromatin markers

  • Cytoplasmic localization:

    • May reflect role in protein modification via neddylation pathway

    • Could indicate interaction with cytoplasmic signaling components

    • Analyze for pattern changes during stress response

  • Dynamic localization changes:

    • Cell cycle-dependent changes may indicate regulatory function

    • Stress-induced relocalization would support role in stress response

    • Quantify changes across populations for statistical significance

  • Co-localization analysis:

    • With neddylation pathway components (suggested by function)

    • With stress granules or processing bodies during stress

    • With meiotic structures during sexual differentiation

Correlate localization data with functional studies (gene knockouts, point mutations) to establish causal relationships between localization and function.

How can I integrate BUT1 antibody data with other experimental approaches for comprehensive analysis?

A multi-dimensional approach yields the most comprehensive understanding of BUT1 function:

Integration framework:

  • Combine protein-level data with transcriptomics:

    • Compare BUT1 protein levels (antibody detection) with mRNA expression

    • Analyze correlation between protein abundance and transcript levels under various conditions

    • Identify potential post-transcriptional regulation mechanisms

  • Correlate with genetic studies:

    • Compare antibody-detected phenotypes with knockout phenotypes

    • Use antibody to assess protein levels in point mutants

    • Analyze suppressor or synthetic genetic interactions

  • Link molecular data to physiological outcomes:

    • Correlate BUT1 levels with stress survival rates

    • Analyze relationship between BUT1 localization and cell cycle progression

    • Assess impact of BUT1 modification state on cellular function

  • Data visualization and analysis:

    • Create integrated heatmaps showing protein levels, localization, and phenotypic data

    • Perform statistical analysis to identify significant correlations

    • Develop predictive models for BUT1 function based on integrated datasets

This multi-layered approach can help distinguish correlation from causation and place BUT1 within its biological context more accurately.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.